Asymchem Laboratories Tianjin Co Ltd
SZSE:002821
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
60.13
116.68
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Asymchem Laboratories Tianjin Co Ltd
Other Long-Term Assets
Asymchem Laboratories Tianjin Co Ltd
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Asymchem Laboratories Tianjin Co Ltd
SZSE:002821
|
Other Long-Term Assets
¥369.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Other Long-Term Assets
¥215.7m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Long-Term Assets
¥702.3m
|
CAGR 3-Years
24%
|
CAGR 5-Years
25%
|
CAGR 10-Years
33%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Long-Term Assets
¥928.6m
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
19%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Long-Term Assets
¥84.9m
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Asymchem Laboratories Tianjin Co Ltd
Glance View
In the bustling industrial landscape of Tianjin, Asymchem Laboratories stands as a beacon of innovation and precision in the biopharmaceutical world. Founded with a vision to harmonize the intricate processes of pharmaceutical development, Asymchem has evolved into a powerhouse of Contract Development and Manufacturing Organization (CDMO) services. The company provides end-to-end solutions in the pharmaceutical sector, specializing in the synthesis and manufacturing of small molecule active pharmaceutical ingredients (APIs). Their sophisticated laboratories and state-of-the-art production facilities serve a global clientele, demanding not only high-quality standards but also a seamless integration of complex processes—from drug discovery through commercialization. Asymchem's business model thrives on the symbiosis between its technical expertise and the ever-growing demand for innovative pharmaceuticals. They offer a comprehensive suite of services including research and development, process optimization, and full-scale commercial production. The company's revenue streams are tied to its ability to win long-term contracts with major pharmaceutical companies, focusing on creating custom-tailored solutions that expedite the drug development timeline while ensuring compliance with stringent regulatory standards. By aligning their operations with the needs of the biopharmaceutical industry, Asymchem secures its positioning as a key player, propelling forward the possibilities of modern medicine while ensuring sustainable growth in the competitive pharmaceutical manufacturing sector.
See Also
What is Asymchem Laboratories Tianjin Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
369.8m
CNY
Based on the financial report for Sep 30, 2024, Asymchem Laboratories Tianjin Co Ltd's Other Long-Term Assets amounts to 369.8m CNY.
What is Asymchem Laboratories Tianjin Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
20%
Over the last year, the Other Long-Term Assets growth was -44%. The average annual Other Long-Term Assets growth rates for Asymchem Laboratories Tianjin Co Ltd have been -7% over the past three years , 20% over the past five years .
You don't have any saved screeners yet
